Alessandro Bellapianta

Mr. Alessandro Bellapianta

Johannes Kepler University of Linz, Linz, Oberösterreich, Austria
+1
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
ABAlessandro Bellapianta
Alessandro Bellapianta
ACAna Cetkovic
Ana Cetkovic
MBMatthias Bolz
Matthias Bolz
Ahmad SaltiAhmad Salti
Ahmad Salti
Despite the progress of modern medicine in the last decades, millions of people diagnosed with retinal dystrophies (RDs), such as retinitis pigmentosa, or age-related diseases, such as age-related macular degeneration, are suffering from severe visual impairment or even legal blindness. On the one hand, the reprogramming of somatic cells into induced pluripotent stem cells (iPSCs) and the progress of three-dimensional (3D) retinal organoids (ROs) technology provide a great opportunity to study, understand, and even treat retinal diseases. On the other hand, research advances in the field of electronic retinal prosthesis using inorganic photovoltaic polymers and the emergence of organic semiconductors represent an encouraging therapeutical strategy to restore vision to patients at the late onset of the disease. This review will provide an overview of the latest advancement in both fields. We first describe the retina and the photoreceptors, briefly mention the most used RD animal models, then focus on the latest RO differentiation protocols, carry out an overview of the current technology on inorganic and organic retinal prostheses to restore vision, and finally summarize the potential utility and applications of ROs.

Verified
Journal Article
Open access
PDF file
ACAna Cetkovic
Ana Cetkovic
ABAlessandro Bellapianta
Alessandro Bellapianta
MIMihai Irimia-Vladu
Mihai Irimia-Vladu
JHJakob Hofinger
Jakob Hofinger
CYCigdem Yumusak
Cigdem Yumusak
Ahmad SaltiAhmad Salti
Ahmad Salti
Millions of people worldwide are diagnosed with retinal dystrophies such as retinitis pigmentosa and age-related macular degeneration. A retinal prosthesis using organic photovoltaic (OPV) semiconductors is a promising therapeutic device to restore vision to patients at the late onset of the disease. However, an appropriate cytotoxicity approach has to be employed on the OPV materials before using them as retinal implants. In this study, we followed ISO standards to assess the cytotoxicity of D18, Y6, PFN-Br and PDIN individually, and as mixtures of D18/Y6, D18/Y6/PFN-Br and D18/Y6/PDIN. These materials were proven for their high performance as organic solar cells. Human RPE cells were put in direct and indirect contact with these materials to analyze their cytotoxicity by the MTT assay, apoptosis by flow cytometry, and measurements of cell morphology and proliferation by immunofluorescence. We also assessed electrophysiological recordings on mouse retinal explants via microelectrode arrays (MEAs) coated with D18/Y6. In contrast to PFN-Br and PDIN, all in vitro experiments show no cytotoxicity of D18 and Y6 alone or as a D18/Y6 mixture. We conclude that D18/Y6 is safe to be subsequently investigated as a retinal prosthesis.

27 March 2025 in Expert Reviews in Molecular Medicine
Verified
Journal Article
Open access
PDF file
SOSara Ouaidat
Sara Ouaidat
ABAlessandro Bellapianta
Alessandro Bellapianta
FAFranziska Ammer-Pickhardt
Franziska Ammer-Pickhardt
TTTara Taghipour
Tara Taghipour
MBMatthias Bolz
Matthias Bolz
Ahmad SaltiAhmad Salti
Ahmad Salti
Background: The recent emergence of three-dimensional organoids and their utilization as in vitro disease models confirmed the complexities behind organ-specific functions and unravelled the importance of establishing suitable human models for various applications. Also, in light of persistent challenges associated with their use, researchers have been striving to establish more advanced structures (i.e. assembloids) that can help address the limitations presented in the current organoids. Methods: In this review, we discuss the distinct organoid types that are available to date, with a special focus on retinal and brain organoids, and highlight their importance in disease modelling. Results: We refer to published research to explore the extent to which retinal and brain organoids can serve as potential alternatives to organ/cell transplants and direct our attention to the topic of photostimulation in retinal organoids. Additionally, we discuss the advantages of incorporating microfluidics and organ-on-a-chip devices for boosting retinal organoid performance. The challenges of organoids leading to the subsequent development of assembloid fusion models are also presented. Conclusion: In conclusion, organoid technology has laid the foundation for generating upgraded models that not only better replicate in vivo systems but also allow for a deeper comprehension of disease pathophysiology.

2 November 2025 in Advanced Functional Materials
Verified
Journal Article
Open access
ACAndrea Corna
Andrea Corna
KGKatarina Gugujonovic
Katarina Gugujonovic
MSManuela Schiek
Manuela Schiek
ABAlessandro Bellapianta
Alessandro Bellapianta
PWPaul Werginz
Paul Werginz
GZGünther Zeck
Günther Zeck
Organic semiconductors are emerging as a promising class of photovoltaic materials for neural interfaces, offering high power conversion, mechanical flexibility, biocompatibility, and tunable optoelectronic properties. In this study, the application of a D18:Y6‐based organic photovoltaic (OPV) electrode is investigated for subretinal stimulation in a model of retinal degeneration. It is demonstrated that OPV devices can be engineered to electrically stimulate the retina via network‐mediated pathways, in a manner comparable to established neurostimulation approaches. The presented OPV electrodes reliably activate retinal ganglion cells, eliciting consistent spike responses to light pulses within the near‐infrared range. The stimulation onset, spike latency, and response profiles suggest effective faradaic charge injection as a key mechanism for neuronal activation, particularly for longer pulse durations. Moreover, it is shown that both light intensity and pulse duration can be used to finely tune the neural response, offering a high degree of control over retinal ganglion cell activation. Finally, it is proven that D18:Y6 blend is biocompatible in vitro when in direct contact with human induced pluripotent stem cell (iPSC)‐derived retinal organoids and mouse explants. These results validate the photo‐electrical performance and biocompatibility of D18:Y6 OPVs and position them as a viable candidate for next‐generation, minimally invasive retinal prosthetics.

24 December 2025 in Biomedicines
Verified
Journal Article
Open access
PDF file
ABAlessandro Bellapianta
Alessandro Bellapianta
JQJingjing Qi
Jingjing Qi
Michele GiuglianoMichele Giugliano
Michele Giugliano
SOSara Ouaidat
Sara Ouaidat
Rana El RawasRana El Rawas
Rana El Rawas
Ahmad SaltiAhmad Salti
Ahmad Salti
Background: Retinitis pigmentosa (RP) encompasses a group of inherited retinal disorders characterized by progressive degeneration of rod and cone photoreceptors, leading to vision loss. Among RP subtypes, RP11 is linked to mutations in PRPF31, a key spliceosome component, resulting in retinal cell dysfunction. Although PRPF31 is ubiquitously expressed, its mutations predominantly impact retinal cells, leading to the progressive loss of photoreceptors. Despite significant progress, studies have focused on photoreceptor and retinal pigment epithelium dysfunction in late disease stages, leaving early molecular events and the involvement of other retinal cell types unresolved. Moreover, comprehensive single-cell analyses capturing dynamic transcriptional changes across all retinal populations at early and late differentiation stages are still lacking. Methods: Using patient-derived retinal organoids (ROs), this study investigates the impact of PRPF31-RP11 mutation through a series of morphological, functional, molecular, and transcriptomics analyses. Results:. Single-cell RNA sequencing revealed dynamic gene expression related to early Müller glia activation, retinal ganglion cell distress, and progressive photoreceptor degeneration. Findings identify dysregulated molecular pathways associated with phototransduction, oxidative stress, and inflammation. Conclusions: Our results support a specific RO model of RP11 in which PRPF31 mutation recapitulate in vitro key features of RP, while simultaneously eliciting compensatory or modulatory responses in other retinal cell types.

2 October 2025 in Research Square
Verified
Preprint
Open access
PDF file
ABAlessandro Bellapianta
Alessandro Bellapianta
JQJingjing Qi
Jingjing Qi
MGMichele Giugliano
Michele Giugliano
SOSara Ouaidat
Sara Ouaidat
Rana El RawasRana El Rawas
Rana El Rawas
Ahmad SaltiAhmad Salti
Ahmad Salti
Retinitis pigmentosa (RP) encompasses a group of inherited retinal disorders characterized by progressive degeneration of rod and cone photoreceptors, leading to vision loss. Among RP subtypes, RP11 is linked to mutations in PRPF31, a key spliceosome component, resulting in retinal cell dysfunction. Although PRPF31 is ubiquitously expressed, its mutations predominantly impact retinal cells, leading to the progressive loss of photoreceptors. Despite significant progress, studies focused on photoreceptor and retinal pigment epithelium dysfunction in late disease stages, leaving early molecular events and the involvement of other retinal cell types unresolved. Moreover, comprehensive single-cell analyses capturing dynamic transcriptional changes across all retinal populations at early and late differentiation stages are still lacking. Using patient-derived Retinal Organoids (ROs), this study investigates the developmental trajectory of PRPF31-RP11 mutation through a series of morphological, functional, molecular and transcriptomics analysis. Our results show that ROs recapitulate in vitro key features of RP, including photoreceptor loss and functional impairment. Single-cell RNA sequencing revealed early Müller glial expansion, retinal ganglion cell stress, and progressive photoreceptor degeneration. Findings identify dysregulated molecular pathways associated with phototransduction, oxidative stress, and inflammation, providing insights into RP11 pathogenesis and potential therapeutic targets.